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7Introduction
(SP-4-2)-diamminedichloridoplatinum(II) (cisplatin) and many of
its analogs are currently used in the treatment of testicular and
ovarian cancers and increasingly in other types of solid tumors
[1]. The cytotoxic effect of cisplatin is thought to be associated
with platination of DNA bases, predominantly guanine, formation
of intrastrand cross-links, and induction of DNA bending [2].
Damage to DNA eventually causes apoptotic cell death through
a complex cascade of biochemical processes. Although DNA
represents the probable primary target for this metallodrug, only
a very modest fraction of the administered cisplatin reacts with
nuclear DNA producing the critical cytotoxic lesions. The largest
amount of cisplatin is known to bind extracellular and intracellular
proteins, reacting with methionine and cysteine residues [3].
These interactions, explored only marginally, are probably
responsible for the relevant toxic side effects caused by platinum
drugs andmight also play some role in the anticancer mechanism.
Moreover, the reactions with sulfur-containing proteins such as
metallothioneins have been associated with cellular resistance
against platinum drugs. In this context, a crucial role is played
by the interactions between platinum drugs, including cisplatin,
and a number of potentially platinum-binding cysteine-rich
proteins, such as those containing zinc ﬁnger domains, generally
indicated as CCCC (steroid receptor), CCHH (cellular or transcription
factor), and CCHC (retroviral nucleocapsid proteins) boxes. It is
known that cisplatin irreversibly binds human polymerase alpha
[4], which contains a CCCC zinc ﬁnger domain. Details on the
binding mechanism of cisplatin to the DNA binding motif of
human polymerase alpha and polymerase kappa, the latter
containing a CCHC zinc ﬁnger domain, have been recently
reported by Volckova et al. [5]. These authors demonstrated that,
upon binding to cisplatin, CCCC and CCHC zinc ﬁnger domains
release zinc ions, undergoing dramatic structural modiﬁcations.J. Pept. Sci. 2013; 19: 227–232Other studies have shown that trans-platinum derivatives are
capable of ejecting zinc ion from a CCHC-type zinc ﬁnger domain
of the HIV-1 nucleocapsid protein (NCp7) [6,7] and exerting
antiretroviral activity [6]. It is worth noting that CCHC zinc binding
domains with very high amino acid sequence and functional
homology to corresponding domains of retroviral nucleocapsid
proteins are present in CNBPs, also known as CCHC-type zinc
ﬁnger CNBPs [8]. This class of highly homologous proteins is
found in humans and other vertebrates. Although the biological
functions of CNBPs are still under investigation, the striking
conservation in various organisms suggests that CNBPs play a
fundamental biological role across different species. In fact, the
available biological and structural data indicate that CNBPs are
implicated in transcriptional and posttranscriptional control of
many genes and cell proliferation [9]. In view of the biological
and pharmacological relevance of the interactions between
platinum drugs and proteins with CCHC-type zinc ﬁnger domain,Copyright © 2013 European Peptide Society and John Wiley & Sons, Ltd.
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8we have investigated the interaction between cisplatin and a zinc
ﬁnger peptide of CCHC type with a general sequence, -Cys-f-X-
Cys-Gly-+-X2-Gly-His-X3-d-Cys-, where X is a variable amino acid,
f is an aromatic residue, + is a charged residue, and d is a side-
chain carbonyl-containing residue. We have chosen this zinc
ﬁnger peptide, hereafter denoted as peptide–Zn, as a model
peptide. It corresponds to the ﬁrst zinc knuckle of EIAV NCp11
and shows very high sequence homology with other lentiviral
NCps, such as HIV-1 NCp7 and HIV-2 NCp8, and also with zinc
ﬁnger motifs found in the human CNBPs. The binding properties
of this peptide to Co(II) and Zn(II) ions were reported in a previous
investigation [10]. ESI-MS and 1D and 2D 1H NMR spectroscopy
studies of the reaction between cisplatin and the (PyrZf18)–Zn
complex provide evidence for zinc ejection and the formation of
the (PyrZf18)–platinum–(NH3)2 complex that eventually converts
into the mono-amino derivative (PyrZf18)–platinum–(NH3).Materials and Methods
Peptide Synthesis
Protected Na-Fmoc amino acid derivatives and coupling reagents
were purchased from Inbios srl (Napoli, Italy), and Fmoc-PAL-PEG-PS
resin from Applied Biosystems (Foster City, CA, USA). All other
chemicals were purchased from Sigma-Aldrich (Bucks, Switzerland)
and were used as received, unless otherwise stated. The synthesis
of the 18-amino-acid peptide (H-QTCYNCGKPGHLSSQCRA-NH2)
was carried out in solid phase under standard conditions using
the Fmoc strategy on Fmoc-PAL-PEG-PS resin (0.73mmol/g) on a
Pioneer ﬂow peptide synthesizer (Applied Biosystems). The scale
synthesis was 0.1mmol. The peptide was cleaved from the solid
support by suspending the resin in a TFA (88%), phenol (4%),
EDT (2%), thioanisol (3%), and H2O (3%) mixture for 3 h at room
temperature. The mixture was then ﬁltered, and the solution
was concentrated under vacuum. The crude product was
precipitated by adding cold ether, the liquid phase was removed
by ﬁltration, and the solid was suspended in water/0.1% TFA and
then was recollected after lyophilization (160mg). The product
was analyzed by RP-HPLC (Shimadzu, Kyoto, Japan; LC-20AD) on
a C18 Phenomenex (Torrance, CA, USA) column (10mm 250mm,
300-Å pore size, 5-mm particle size) with a linear gradient of 5–40%
(v/v) acetonitrile containing 0.1% (v/v) TFA over 20min. The
spontaneous partial cyclization of the glutamine N-terminal
residue was observed to give a pyroglutamic derivative. N-terminal
glutamine (Zf18) and pyroglutamic acid (PyrZf18) peptides were
separated using RP-HPLC (tR 6.0min for Zf18 and tR 12.0min for
PyrZf18). In a subsequent synthesis, cyclization was completed
by treating 13.5mg of the crude peptide with 13.50ml of acetic
acid for 6 days at room temperature. The desired compound was
obtained at HPLC purity higher than 95% with a ﬁnal 35% yield.
The identity was conﬁrmed by ESI [Zf18 [M+ 1] = 1954 a.m.u.
(calculated 1953.07), PyrZf18 = [M+1] = 1935 a.m.u. (calculated
1936.07)]
CD Spectroscopy
CD spectra were recorded on a Jasco J-600 spectropolarimeter
(Jasco, Easton, MD, USA) using a 0.1-cm-path-length cylindrical
quartz cell. A peptide sample (PyrZf18) of 125mM in a 10mM
sodium phosphate buffer at pH 7.5 was reduced with TCEP. ZnCl2
was dissolved in water at a concentration of 1mM and added towileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Pepeptide 30min before recording the spectra. Data were acquired
at 20 C and were baseline corrected by subtraction of buffer/
TCEP and/or buffer/TCEP/ZnCl2. In each case, the ﬁnal spectrum
is the sum of 16 separate spectra with a 0.1-nm step resolution,
a 2-s time constant, a 50-nm/min scan speed, a 1-nm bandwidth,
and a 20-mdg sensitivity.UV–visible Spectroscopic Investigation
A solution containing PAR (50mM) [11], ZnCl2 (50mM), and reduced
peptide (PyrZf18; 50mM) was prepared and used to record the
absorption spectra in the 340–600-nm range using a Varian CARY-
5E UV-Vis-NIR spectrophotometer (Palo Alto, CA, USA). Identical
conditions were adopted when cisplatin (to a ﬁnal concentration
of 100mM) was added to the PAR–(PyrZf18)–zinc complex.Mass Spectrometry
ESI-MS data were obtained using a Finnigan Surveyor MSQ single
quadrupole ESI mass spectrometer coupled with a Finnigan
Surveyor (Finnigan/Thermo Electron Corporation, San Jose, CA,
USA). One milligram of PyrZf18 (5.0 104mol) was dissolved
in 1.0ml of phosphate buffer, pH 7.4. The solution was kept in
inert atmosphere, and 400 ml of TCEP (0.1mM) in NaOH (1.0 M)
was added. The mixture was stirred overnight, and the reduction
of a sulfur bridge was tested by MALDI-TOF MS: calculated
[M+H]+ m/z 1935.8, found m/z 1936.7. One hundred twenty-ﬁve
microliters of cisplatin, previously dissolved in water (concentration
3.3mM), was added to the buffer. After 48 h at room temperature,
the sample was analyzed by ESI-MS: calculated [M+3H]3+ 722.6,
found m/z 721.0. The mixture was divided into two vials. One
portion was stirred at room temperature for 7 days. The coordina-
tion was checked again by ESI-MS: calculated [M+ 3H]3+ = 715.6,
found m/z 716.0. Six microliters of aqueous solution of ZnCl2
(1mM) was added to the other portion. The mixture was stirred
for 48 h, and then ESI-MS spectra were taken.NMR Spectroscopy
(Zf18)–Zn was prepared by dissolving the peptide at 2.5mM in
80% H2O–20% D2O. The pH was adjusted to 7.0, and 1.2
equivalents of ZnCl2 were added to form the complex. The non-
thiol-reducing agent TCEP was added to prevent the oxidation
of cysteine residues.
The (PyrZf18) platinum complex was prepared by dissolving
the peptide in 80% H2O–20% D2O (buffer sodium phosphate,
pH 7) and then adding cisplatin in slight excess (1.2 equivalents)
with respect to the PyrZf18 concentration of 1.8mM. TCEP was
added also to this sample. A tenfold diluted sample was used
to check possible aggregation.
NMR data were collected using a VARIAN Unity Inova 500-MHz
spectrometer (Palo Alto, CA, USA) with sample at 298 K. Chemical
shifts were referenced to the methyl resonance of 4,4-dimethyl-4-
silapentane-1-sulfonic acid used as the internal standard. Proton
chemical shift assignments were obtained from TOCSY [12,13]
and NOESY [14] experiments. In TOCSY and NOESY experiments,
the water signal was suppressed by a 2.5 presaturation pulse. 2D
experiments were recorded in phase-sensitive mode using the
States method [15]. Mixing times were 50 and 80ms for the TOCSY
spectra and 200ms for the NOESY spectrum.ptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 227–232
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Figure 2. ESI mass spectra of (A) (PyrZf18)–platinum–(NH3)2 and (B)
INTERACTION OF CISPLATIN WITH A CCHC ZINC FINGER MOTIFResults
A nucleocapsid zinc ﬁnger peptide with sequence H-QTCYNCGKP
GHLSSQCRA-NH2, corresponding to the ﬁrst zinc knuckle of
EIAV NCp11, was used as the model peptide. The synthesis was
carried out on solid phase using the standard Fmoc protocol.
The N-terminal glutamine residue of peptide undergoes partially
nonenzymatic spontaneous cyclization, resulting in the formation
of pyroglutamic acid during the cleavage process. The HPLC
puriﬁcation allowed us to isolate both PyrZf18 and Zf18 products.
To obtain only pyroglutamic acid at the N-terminal position,
the conversion was completed by dissolving the peptide in
acetic acid for 6 days. PyrZf18 was used in all the experimental
investigations except for measuring the 1H NMR spectra of the
zinc–peptide complex in which Zf18 was used.
We used PAR to qualitatively demonstrate zinc ejection from
this CCHC nucleocapsid zinc ﬁnger as previously reported [6,16].
PAR is a tridentate ligand forming ML2-type complexes with Zn(II)
and other transition metals and is used to measure micromolar
concentrations of these metals [11]. Free PAR absorbs at
~410 nm, whereas the PAR2–Zn
2+ complex shows an absorption
maximum at ~500 nm.
Preliminary tests were performed to verify if PAR could be
efﬁciently used in the studied system. The zinc ﬁnger PyrZf18
was able to displace zinc ions from the PAR2–Zn complex
although to a lesser extent than EDTA. In fact, it lowered the
maximum at 500 nm when added (1 : 1 peptide/zinc molar ratio)
to a solution containing the PAR2–Zn complex. The observed
smaller efﬁciency in the displacement is in agreement with the
measured lower afﬁnity constant of the peptide–zinc complex
(1012M1) comparedwith EDTA–zinc (1013.65 M1). No interferences
were observed in the PAR2–Zn absorption spectrum because of
cisplatin and/or TCEP. In addition, the absorption spectrum of
the (PyrZf18)–Zn complex solution in the presence of PAR
and TCEP remained unchanged for more than 24 h under our
experimental conditions.
Upon addition of cisplatin to a solution containing the
peptide–Zn complex and PAR, a slow growth of the typical
PAR2–Zn absorption band at ~500 nm was observed (Figure 1).
Furthermore, the peptide that had reacted with cisplatin in a
1 : 1 molar ratio for 48 h, when added to the PAR2–Zn solution,
was unable to displace zinc from the PAR2–Zn complex. On the
contrary, the free peptide immediately lowered the PAR2–Zn
absorption at 500 nm as previously mentioned. To conﬁrm our0.15
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Figure 1. Absorption spectrum of 50mM PAR, 10mM Zn2+, and 50mM
peptide in phosphate buffer, pH 7.4, at 25 C. Spectra taken 1 h (□) and
24 h (●) after the addition of 100mM cisplatin.
J. Pept. Sci. 2013; 19: 227–232 Copyright © 2013 European Peptide Society aﬁndings, we used ESI-MS analysis that provided clear evidence
for the formation of the (PyrZf18)–platinum–(NH3)2 complex
(48 h reaction time), showing a typical Pt isotopic pattern.
Moreover, ESI-MS spectra taken after 7 days revealed that it
converts into the (PyrZf18)–platinum–NH3 complex (Figure 2).
The addition of a zinc chloride solution to the (PyrZf18)–
platinum–(NH3)2 and to the (PyrZf18)–platinum–NH3 complex
and MS analyses after 48h indicated that the complexes are stable
in the presence of equimolar zinc ion concentrations.
The effect of Zn2+ and Pt2+ on peptide secondary structures
was investigated by CD and NMR spectroscopies. Figure 3 shows
the CD spectra of the (PyrZf18), the (PyrZf18)–zinc complex, and
the (PyrZf18)–platinum complex obtained after the reaction
of cisplatin and peptide for 7 days. The CD spectrum of the(PyrZf18)–platinum–(NH3).
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Figure 3. CD spectra of peptide alone (—) and in the presence of 2
equivalents of cis-Pt (●) or ZnCl2/Zn ﬁnger (□). The data were expressed
in terms of [θ], the molar ellipticity.
nd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
2
2
9
CASTIGLIONE MORELLI ET AL.
2
3
0peptide in the absence of zinc is compatible with random coil
conformations. In the presence of zinc (molar ratio zinc/(PyrZf18)
2 : 1), the CD spectrum of the (PyrZf18)–Zn complex shows a
pronounced, less negative ellipticity with respect to the free
peptide spectrum and a positive ellipticity between 190 and
195 nm, but no shift of the minimum. These features are
indicative of the onset of more ordered structures. The effects
of zinc on peptide were completely reversed by the addition of
10mol of EDTA per mole of zinc. The CD spectrum of the
peptide–platinum complex undergoes a blueshift of the
ellipticity minimum with respect to both the previously described
spectra; therefore, the synthetic peptide is partially folded
upon reaction with cisplatin although it apparently shows more
random conformation with respect to the zinc complex.
The 1H 1D NMR spectrum was measured to conﬁrm the
platinum binding to the peptide. The spectrum in the absence
of the ion shows poor dispersion of the amide proton
resonances, indicating that the peptide does not adopt an
ordered conformation in these experimental conditions. After
7 days upon the addition of 1.2 equivalents of cisplatin, a more
marked dispersion of the resonances of the amide protons was
observed in the NMR spectrum. The sequential resonance
assignment for the cisplatin–peptide complex was performed
according to the standard method established by Wuthrich [17].
From the amide protons, TOCSY (Figure 4) experiments allowed
identiﬁcation of the a and b protons of almost all the amino acids.
NOESY cross-peaks connecting HN of residue i with HN and/or Ha
and Hb of residue i+ 1 were used for sequential assignment. As
already observed in the zinc–(Zf18) complex and in the whole
EIAV NCp11 [10], Cys3 shows a medium-range NOE between its
CbH and NH of Cys
6 (position i+ 3), but different from the zinc
complex, it did not present NOEs with residues at positions i+4
and i+ 5. The number of the cross-peaks in the TOCSY ﬁngerprint
region was greater than the expected 17 peaks (one residue has
no amide proton because it is a Pro). This could be ascribed
neither to the peptide, because MS and HPLC analysis conﬁrmed
peptide purity, nor to aggregation as we had no evidence of
NMR line-width variations, at least in the concentration range of
0.18–1.8mM. Furthermore, we could also exclude that the extraFigure 4. Fingerprint region of the 1H NMR 500-MHz TOCSY spectrum of
the platinum–(PyrZf18) complex (mixing time, 80ms).
wileyonlinelibrary.com/journal/jpepsci Copyright © 2013 European Pepeaks in the spectra were due to the presence of cis–trans
equilibrium around the Lys8-Pro9 peptide bond because we
observed a strong sequential NOE between the Lys8 CaH
and the Pro9 CdH2, thus indicating that proline adopts the
trans-conformation. Almost all the assigned residues in the
platinum–(PyrZf18) peptide complex have chemical shifts very
similar to those observed for the corresponding residues in
the zinc–(Zf18) complex (Table 1) [10], thus suggesting that
peptide local conformations in the two metal complexes are
quite similar at least for certain residues. An evident and
interesting exception is His11, which in the zinc complex is
involved in the metal coordination through its Ne atom, so its
H2 and H4 protons experience upﬁeld chemical shifts, whereas
in the platinum complex, this residue is not involved in metal
binding, so the histidine aromatic protons have chemical shifts
close to their random coil values. The other three metal binding
residues, the cysteines, appear to be involved in the coordination
through their sulfur atoms. This is supported by the fact that in
CCHC zinc ﬁnger domains, the chemical shifts of Cys residues
involved in metal binding are quite typical and well conserved.
We did not try to perform the assignment of the extra peaks
observed in the NMR spectra.Discussion
The obtained results allow us to conclude that cisplatin irreversibly
blocks the zinc binding groups in the free peptide and is able to
slowly eject zinc from the zinc–peptide complex. The observed
end product of the reaction with cisplatin is a complex in which
only one ammonia is coordinated to platinum. Very likely, after
an initial binding with two cysteine residues and the formation
of the (PyrZf18)–platinum–(NH3)2 complex, a release of one
ammonia molecule occurs because of trans-labilization, and then
the third cysteine is coordinated, leading to a mixture of isomers
and/or conformers of the (PyrZf18)–platinum–NH3 complex,
which could explain the observed TOCSY extra peaks.
We have not tried to fully characterize the (PyrZf18)–platinum–
NH3 and the (PyrZf18)–platinum–(NH3)2 square planar complexes;
in particular, we have not investigated the isomers of these
complexes. However, it is clear from the NMR study that the His
residue is not involved in the platinum coordination; therefore,
the only isomers that can be predicted for (PyrZf18)–platinum–
NH3 and (PyrZf18)–platinum–(NH3)2 are those reported in Figure 5.
On the other hand, it is possible to speculate that the isomeric
composition of the complexes should depend on the relative
reactivity (nucleophilicity/accessibility) of thiol/thiolate groups in
the zinc ﬁnger coordination site. For example, it is known that in
the case of HIV-1 NCp7, the CCHC cores are reactive to soft
electrophiles. Although each of the two conserved NCp7 zinc
ﬁngers share the same retroviral zinc ﬁnger motif, the core of the
C-terminal ﬁnger is substantially more reactive than the N-terminal
ﬁnger, and Cys49 is the most labile site of NCp7 [18,19]. With this
taken into account, it is reasonable to assume that both the
chemical composition of the CCHC zinc ﬁnger core and its local
protein environment can tune the reactivity of these zinc ﬁnger
motifs toward cisplatin and determine the type and abundance
of the isomers formed. However, the stoichiometry of the
complexes reported here should be common to different CCHC
zinc proteins. In this context, it is worth noting that in the case of
a 31-amino-acid CCCC zinc ﬁnger [20], the complete displacement
of zinc ion was only observed when two platinum ions were linkedptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2013; 19: 227–232
Table 1. 1H NMR chemical shifts of the studied peptides at 298 K, in 90% H2O–10% D2O, pH 7
Q1
Residue
NH CaH CbH CgH CdH CeH Others
pE1 8.32 4.38 2.15 2.35
T2 8.68 4.35 4.16 1.25
8.38 4.30 4.10 1.19
C3 8.11 4.18 2.98/2.55
8.10 4.17 2.94/1.97
Y4 8.74 4.90 3.10/2.50 7.13d/6.82e
8.75 4.80 3.20 7.12d/6.84e
N5 9.54 4.70 3.10/2.85
9.56 4.62 3.10/2.82
C6 8.77 4.80 3.31/2.68
8.78 4.90 3.22/2.63
G7 7.95 3.85/3.65
7.87 4.13/3.87
K8 8.22 4.36 1.90/1.78 1.65 1.41 3.00
8.27 4.40 1.95 1.65 1.55 2.90
P9 4.42 2.32/2.05 1.92 3.78/3.60
4.39 2.30/2.03 1.90 3.85/3.68
G10 8.62 4.15/3.70
8.53 3.94/3.63
H11 7.17 4.49 3.17/3.07 7.45e/6.96d
7.18 4.38 3.27 8.04«/7.06d
L12 8.27 4.62 1.65 0.90
8.19 4.34 1.60 1.45 0.90/0.85
S13 9.02 4.47 3.91
8.99 4.40 3.99
S14 7.89 4.12 3.87
7.92 4.27 4.03/3.90
Q15 8.03 4.47 2.15 2.44 7.41/6.90
8.05 4.50 2.29 2.40/2.32 7.59/6.96
C16 7.62 3.78 3.10/2.91
7.48 3.75 3.39/3.00
R17 7.93 4.07 1.97 1.32/1.21 2.95 6.87
8.06 4.02 1.78 1.45 2.92
A18 8.42 4.22 1.40
8.38 4.37 1.30
For each residue, the ﬁrst line refers to the zinc complex: [ZnCl2] = 2.2mM and [Zf18] = 2.5mM; the second line, in bold italics, reports data for the
platinum complex: [cisplatin] = 2.2mM and [PyrZf18] = 1.8mM.
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Figure 5. Scheme of all available isomers of (PyrZf18)–platinum–(NH3)2
and (PyrZf18)–platinum–(NH3) complexes.
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1to the peptide; in another case, all the four cysteines of a 35-amino-
acid CCCC zinc ﬁnger peptide were coordinated to a single Pt2+ ion
with the release of two ammonia molecules of cisplatin [21]. As
reported earlier, trans-platin compounds have been studied as
potential antiretroviral agents targeting the nucleocapsid protein
NCP7 of HIV-1, whereas cisplatin derivatives have not been
considered. This is very likely due to a few anecdotal reports on
cisplatin cancer treatment of HIV-1-infected patients. In certain
cases, no effect of cisplatin on HIV-1 progression has been
reported [22], whereas in other circumstances, with a combination
chemotherapy with cisplatin, a progressive HIV disease has been
experienced after therapy [23]; this could be due to a cisplatin
stimulation of HIV replication [24–26]. However, carboplatin, a
platinum(II) derivative with cis-geometry as opposed to cisplatin,
does not stimulate the expression of the HIV long terminal repeat
sequences [27]. Therefore, considering these results, we suggestnd John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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2that other platinum(II) derivatives with cis-geometry different from
cisplatin could eventually be investigated as antiretroviral agents.
Finally, our ﬁndings indicate a potential interference of cisplatin
with the CNBP functions.References
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